Reported Reactions

Devices › Stent, superficial femoral artery

Device brand name · Stent superficial femoral artery

GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface: medical device reports filed with FDA

341 reports name it, 2020–2026. Manufacturer given most often on reports: W L Gore & Associates. Product code NIP.

341
device reports naming the brand
0% of all MAUDE reports · about 57 a year
91
reports, 12 months to August 2026
80 in the 12 months before
40.5%
classified as malfunction
51.3% across the product code
0.6%
classified as death, as reported
2 reports · not verified by FDA

FDA's MAUDE database holds 341 reports that name the brand "GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface" (stent superficial femoral artery), received between July 2020 and August 2026; the manufacturer given most often on reports is W L Gore & Associates. Spellings of one product vary from report to report.

91 reports arrived in the 12 months to August 2026, up 14% from 80 in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (58.9%), malfunction (40.5%) and death (0.6%); across all stent, superficial femoral artery reports (product code NIP) death is recorded in 1.8% and malfunction in 51.3%. Event type is the reporter's classification of the report, not a verified outcome.

The device problems coded most often are activation failure (23.8%), device stenosis (15.2%) and complete blockage (8.5%). The patient problems coded most often are obstruction/occlusion, thrombosis/thrombus and stenosis. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Reports by month, five years

0713Sep 2021: 2Oct 2021: 1Nov 2021: 5Dec 2021: 52022Jan 2022: 2Feb 2022: 2Mar 2022: 1Apr 2022: 2May 2022: 2Jun 2022: 4Jul 2022: 0Aug 2022: 6Sep 2022: 0Oct 2022: 1Nov 2022: 0Dec 2022: 02023Jan 2023: 0Feb 2023: 0Mar 2023: 3Apr 2023: 1May 2023: 4Jun 2023: 5Jul 2023: 8Aug 2023: 5Sep 2023: 4Oct 2023: 4Nov 2023: 0Dec 2023: 52024Jan 2024: 6Feb 2024: 1Mar 2024: 4Apr 2024: 5May 2024: 7Jun 2024: 0Jul 2024: 6Aug 2024: 13Sep 2024: 5Oct 2024: 5Nov 2024: 6Dec 2024: 102025Jan 2025: 12Feb 2025: 2Mar 2025: 9Apr 2025: 11May 2025: 5Jun 2025: 8Jul 2025: 4Aug 2025: 3Sep 2025: 8Oct 2025: 7Nov 2025: 4Dec 2025: 112026Jan 2026: 8Feb 2026: 4Mar 2026: 5Apr 2026: 6May 2026: 9Jun 2026: 10Jul 2026: 13Aug 2026: 6

Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.

By year received

042842020: 2520202021: 4420212022: 2020222023: 3920232024: 6820242025: 8420252026: 612026

Event type and report source

Event type, as classified on the report

Death0.6%2
Injury58.9%201
Malfunction40.5%138
Other0%0
Not given0%0

Who filed the report

Manufacturer report100%341
Voluntary report0%0
User facility report0%0
Distributor report0%0
Not given0%0

Grey bar: all 10,627 reports carrying product code NIP. Event type is the filer's classification and is not verified by FDA.

Device problems coded

Device problem (FDA code)ReportsShareShare across product code
Activation failure8123.8%12.1%
Device stenosis5215.2%0.7%
Complete blockage298.5%0.8%
Breakthe device broke267.6%8.7%
Obstruction of flow267.6%1.6%
Insufficient device problem information247%1.6%
Patient-device incompatibilitythe device did not suit the patient175%0.9%
Detachment of device or device componentpart of the device came off154.4%4.1%
Device endoleak154.4%0.3%
Material fragmentation154.4%0.3%
Material separation154.4%6.3%
Deformation due to compressive stress144.1%0.7%
Failure to advance102.9%2.9%
Fracturea broken bone102.9%9.5%
Migrationthe device moved from where it was placed102.9%1.3%
Microbial contamination of device92.6%0.1%
Separation failure92.6%0.3%
Activation problem82.3%0.5%
Partial blockage82.3%0.5%
Difficult to removethe device was hard to remove72.1%7.8%

FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.

Patient problems coded

Patient problem (FDA code)ReportsShare
Obstruction/occlusion6418.8%
Thrombosis/thrombus5315.5%
Stenosis277.9%
Clinical endoleak236.7%
Occlusion154.4%
Reduced blood flow113.2%
Aneurysm102.9%
Bacterial infectiona bacterial infection92.6%
Hemorrhage/blood loss/bleeding72.1%
Renal impairmentreduced kidney function61.8%
Ischemia51.5%
Foreign body in patientpart of a device left in the patient41.2%
Pseudoaneurysm41.2%
Stroke/cva41.2%
Aneurysm expansion30.9%

Patient problem codes are present mainly in reports filed since 2019 and are often blank.

In context

MeasureGORE VIABAHN Endoprosthesis with PROPATEN Bioactive SurfaceProduct code NIPAll MAUDE reports
Reports34110,62726,136,888
Share of that pool—3.2%0%
Classified as death, per 1,000 reports6189
Classified as injury58.9%46.8%36.2%
Classified as malfunction40.5%51.3%62.3%
Filed by the manufacturer100%97.8%94.9%

Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Other brands with product code NIP

BrandReportsLatest 12 monthsClassified as death
Supera Self-Expanding Stent System1,72600.9%
GORE VIABAHN Endoprosthesis with HEPARIN Bioactive Surface9061742.1%
Innova868320.7%
GORE VIABAHN Endoprosthesis985185.8%
BioMimics 3D Vascular Stent System581100%
Supera5171594.6%
Lifestent Solo Vascular Stent System39600%
Everflex Self-Expanding Peripheral Stent With Entrust Delivery System Long385260.5%
LifeStent Vascular Stent34172.9%
LifeStent 5F Vascular Stent333540.6%
Lifestent XL Vascular Stent267200.7%
Supera Peripheral Stent System23633.4%
Innova? Vascular203152%
Everflex Self-Expanding Peripheral Stent With Entrust Delivery System Standard197162%
Lifestent Vascular Stent System20100.5%

Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."

Questions about GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface reports

How many FDA reports name GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface?

341 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 91 in the latest 12 months.

What kinds of events are reported?

injury (58.9%), malfunction (40.5%) and death (0.6%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.

What device problems are coded?

activation failure (23.8%), device stenosis (15.2%), complete blockage (8.5%), break (7.6%) and obstruction of flow (7.6%). These are FDA's device problem codes as entered on the report.

Who files these reports?

manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.

Do these reports show that GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface was at fault?

No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."

How do I report a problem with a medical device?

Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.